Precision Digital Health has broadened its service offering by partnering with 23andMe to resell genotyping services for our clients interested in adding genomic and phonemic data sets to their research. 23andMe is currently the only genetic service direct to consumer that includes genetic reports that meet FDA standards for clinical research. Our SUMMA™ platform already supports native interoperability for over 50+ wearables and medical devices, as well as electronic health records (EHR). Now we are adding support and the ability to link 23andMe data to the core clinical data already supported in our SUMMA™ platform ecosystem. With the complexity removed, researchers are now able to perform subject profiling, safety surveillance and advanced analytics using powerful self-service visualizations designed for real-world research for integrated clinical trials.
By providing an end-to-end solution we enable genomic services to be added to any clinical trial hosted on SUMMA™. Our service derives high value from enabling patients to have direct access to their own 23andMe data and reports. This added benefit, to incentivize patients, bolsters recruitment and reduces clinical trial costs. By providing these capabilities across different data assets like genomics, labs, medical devices, wearables and EMR systems, we empower clinical teams for their research with a next generation clinical trial system using advanced analytics.
About Precision Digital Health:
Precision Digital Health is a disruptive global solution provider for clinical trials, Health Economics & Outcomes Research (HEOR) and real-world evidence research to accelerate patient outcomes. Our solutions integrate and precisely assess patients in the real-world to support novel patient-centric endpoints in near real-time. By combining patient data sourced via wearables, genomics, and EHR systems, we reduce time and costs in outcomes research while surfacing clinical insights with advanced analytics in novel disease areas.
